Top

Published in:

01-03-2018 | Original Paper

Lignosulfonic acid attenuates NF-κB activation and intestinal epithelial barrier dysfunction induced by TNF-α/IFN-γ in Caco-2 cells

Authors: Koji Matsuhisa, Akihiro Watari, Kazuki Iwamoto, Masuo Kondoh, Kiyohito Yagi

Published in: Journal of Natural Medicines | Issue 2/2018

Abstract

Lentinula edodes mycelia solid culture extract (MSCE) is used as a medical food ingredient and provides beneficial effects to patients with cancer and chronic type C hepatitis. Low molecular weight lignin (LM-lignin), which is an active component of MSCE, exhibits hepatoprotective, antitumor, antiviral, and immunomodulatory effects. In this study, we investigated the effect of LM-lignin/lignosulfonic acid on intestinal barrier function. Lignosulfonic acid enhanced transepithelial membrane electrical resistance in human intestinal Caco-2 cell monolayers. In Caco-2 cells treated with lignosulfonic acid, expression of claudin-2, which forms high conductive cation pores in tight junctions (TJs), was decreased. Lignosulfonic acid also attenuated the barrier dysfunction that is caused by tumor necrosis factor (TNF)-α and interferon (IFN)-γ in Caco-2 cells. TNF-α- and IFN-γ-induced activation of NF-κB, such as translocation of NF-κB p65 into the nucleus and induction of gene expression, was inhibited by lignosulfonic acid treatment. Furthermore, lignosulfonic acid decreased the TNF-α- and IFN-γ-induced increase in interleukin (IL)-1β and IL-6 expression in Caco-2 cells. These results suggest that lignosulfonic acid not only enhances TJ barrier function but also restores TJ barrier integrity impaired by inflammatory cytokines. Therefore, lignosulfonic acid may be beneficial for the treatment of inflammation-induced intestinal barrier dysfunction observed in inflammatory bowel disease.

Available only for authorised users

Chang R (1996) Functional properties of edible mushrooms. Nutr Rev 54:S91–S93CrossRefPubMed

Chihara G (1992) Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Dev Biol Stand 77:191–197PubMed

Akamatsu S, Watanabe A, Tamesada M, Nakamura R, Hayashi S, Kodama D, Kawase M, Yagi K (2004) Hepatoprotective effect of extracts from Lentinus edodes mycelia on dimethylnitrosamine-induced liver injury. Biol Pharm Bull 27:1957–1960CrossRefPubMed

Watanabe A, Kobayashi M, Hayashi S, Kodama D, Isoda K, Kondoh M, Kawase M, Tamesada M, Yagi K (2006) Protection against d-galactosamine-induced acute liver injury by oral administration of extracts from Lentinus edodes mycelia. Biol Pharm Bull 29:1651–1654CrossRefPubMed

Itoh A, Isoda K, Kondoh M, Kawase M, Kobayashi M, Tamesada M, Yagi K (2009) Hepatoprotective effect of syringic acid and vanillic acid on concanavalin a-induced liver injury. Biol Pharm Bull 32:1215–1219CrossRefPubMed

Itoh A, Isoda K, Kondoh M, Kawase M, Watari A, Kobayashi M, Tamesada M, Yagi K (2010) Hepatoprotective effect of syringic acid and vanillic acid on CCl₄-induced liver injury. Biol Pharm Bull 33:983–987CrossRefPubMed

Okuno K, Uno K (2011) Efficacy of orally administered Lentinula edodes mycelia extract for advanced gastrointestinal cancer patients undergoing cancer chemotherapy: a pilot study. Asian Pac J Cancer Prev 12:1671–1674PubMed

Shen J, Tanida M, Fujisaki Y, Horii Y, Hashimoto K, Nagai K (2009) Effect of the culture extract of Lentinus edodes mycelia on splenic sympathetic activity and cancer cell proliferation. Auton Neurosci 145:50–54. https://doi.org/10.1016/j.autneu.2008.11.004 CrossRefPubMed

Sarkar S, Koga J, Whitley RJ, Chatterjee S (1993) Antiviral effect of the extract of culture medium of Lentinus edodes mycelia on the replication of herpes simplex virus type 1. Antivir Res 20:293–303CrossRefPubMed

10.

Matsuhisa K, Yamane S, Okamoto T, Watari A, Kondoh M, Matsuura Y, Yagi K (2015) Anti-HCV effect of Lentinula edodes mycelia solid culture extracts and low-molecular-weight lignin. Biochem Biophys Res Commun 462:52–57. https://doi.org/10.1016/j.bbrc.2015.04.104 CrossRefPubMed

11.

Yamada T, Oinuma T, Niihashi M, Mitsumata M, Fujioka T, Hasegawa K, Nagaoka H, Itakura H (2002) Effects of Lentinus edodes mycelia on dietary-induced atherosclerotic involvement in rabbit aorta. J Atheroscler Thromb 9:149–156CrossRefPubMed

12.

Tanaka K, Ishikawa S, Matsui Y, Tamesada M, Harashima N, Harada M (2011) Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. Cancer Sci 102:516–521. https://doi.org/10.1111/j.1349-7006.2010.01841.x CrossRefPubMed

13.

Suzuki H, Iiyama K, Yoshida O, Yamazaki S, Yamamoto N, Toda S (1990) Structural characterization of the immunoactive and antiviral water-solubilized lignin in an extract of the culture medium of Lentinus edodes mycelia (LEM). Agric Biol Chem 54:479–487PubMed

14.

Yoshioka Y, Kojima H, Tamura A, Tsuji K, Tamesada M, Yagi K, Murakami N (2012) Low-molecular-weight lignin-rich fraction in the extract of cultured Lentinula edodes mycelia attenuates carbon tetrachloride-induced toxicity in primary cultures of rat hepatocytes. J Nat Med 66:185–191. https://doi.org/10.1007/s11418-011-0580-4 CrossRefPubMed

15.

Kaulmann A, Bohn T (2016) Bioactivity of polyphenols: preventive and adjuvant strategies toward reducing inflammatory bowel diseases—promises, perspectives, and pitfalls. Oxid Med Cell Longev 2016:9346470. https://doi.org/10.1155/2016/9346470 CrossRefPubMedPubMedCentral

16.

Blonski W, Buchner AM, Lichtenstein GR (2011) Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 27:346–357. https://doi.org/10.1097/MOG.0b013e328347aef3 CrossRefPubMed

17.

Hagan M, Cross RK (2015) Safety of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf 14:1473–1479. https://doi.org/10.1517/14740338.2015.1063612 CrossRefPubMed

18.

Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9:799–809. https://doi.org/10.1038/nri2653 CrossRefPubMed

19.

Hering NA, Fromm M, Schulzke JD (2012) Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 590:1035–1044. https://doi.org/10.1113/jphysiol.2011.224568 CrossRefPubMedPubMedCentral

20.

Hasegawa Y, Kadota Y, Hasegawa C, Kawaminami S (2015) Lignosulfonic acid-induced inhibition of intestinal glucose absorption. J Nutr Sci Vitaminol (Tokyo) 61:449–454. https://doi.org/10.3177/jnsv.61.449 CrossRef

21.

Hasegawa Y, Nakagawa E, Kadota Y, Kawaminami S (2017) Lignosulfonic acid promotes hypertrophy in 3T3-L1 cells without increasing lipid content and increases their 2-deoxyglucose uptake. Asian-Australas J Anim Sci 30:111–118. https://doi.org/10.5713/ajas.16.0253 CrossRefPubMed

22.

Qiu M, Wang Q, Chu Y, Yuan Z, Song H, Chen Z, Wu Z (2012) Lignosulfonic acid exhibits broadly anti-HIV-1 activity—potential as a microbicide candidate for the prevention of HIV-1 sexual transmission. PLoS One 7:e35906. https://doi.org/10.1371/journal.pone.0035906 CrossRefPubMedPubMedCentral

23.

Gordts SC, Ferir G, D’Huys T, Petrova MI, Lebeer S, Snoeck R, Andrei G, Schols D (2015) The low-cost compound lignosulfonic acid (LA) exhibits broad-spectrum anti-HIV and anti-HSV activity and has potential for microbicidal applications. PLoS One 10:e0131219. https://doi.org/10.1371/journal.pone.0131219 CrossRefPubMedPubMedCentral

24.

Watari A, Hasegawa M, Yagi K, Kondoh M (2016) Checkpoint kinase 1 activation enhances intestinal epithelial barrier function via regulation of claudin-5 expression. PLoS One 11:e0145631. https://doi.org/10.1371/journal.pone.0145631 CrossRefPubMedPubMedCentral

25.

Watari A, Sakamoto Y, Hisaie K, Iwamoto K, Fueta M, Yagi K, Kondoh M (2017) Rebeccamycin attenuates TNF-alpha-induced intestinal epithelial barrier dysfunction by inhibiting myosin light chain kinase production. Cell Physiol Biochem 41:1924–1934. https://doi.org/10.1159/000472367 CrossRefPubMed

26.

Landy J, Ronde E, English N, Clark SK, Hart AL, Knight SC, Ciclitira PJ, Al-Hassi HO (2016) Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer. World J Gastroenterol 22:3117–3126. https://doi.org/10.3748/wjg.v22.i11.3117 CrossRefPubMedPubMedCentral

27.

Takehara M, Nishimura T, Mima S, Hoshino T, Mizushima T (2009) Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biol Pharm Bull 32:825–831CrossRefPubMed

28.

Lee SH (2015) Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res 13:11–18. https://doi.org/10.5217/ir.2015.13.1.11 CrossRefPubMedPubMedCentral

29.

Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, Said HM (2004) TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 286:G367–G376. https://doi.org/10.1152/ajpgi.00173.2003 CrossRefPubMed

30.

He F, Peng J, Deng XL, Yang LF, Camara AD, Omran A, Wang GL, Wu LW, Zhang CL, Yin F (2012) Mechanisms of tumor necrosis factor-alpha-induced leaks in intestine epithelial barrier. Cytokine 59:264–272. https://doi.org/10.1016/j.cyto.2012.04.008 CrossRefPubMed

31.

Chen S, Zhu J, Chen G, Zuo S, Zhang J, Chen Z, Wang X, Li J, Liu Y, Wang P (2015) 1,25-Dihydroxyvitamin D3 preserves intestinal epithelial barrier function from TNF-alpha induced injury via suppression of NF-kB p65 mediated MLCK-P-MLC signaling pathway. Biochem Biophys Res Commun 460:873–878. https://doi.org/10.1016/j.bbrc.2015.03.125 CrossRefPubMed

32.

Chen SW, Zhu J, Zuo S, Zhang JL, Chen ZY, Chen GW, Wang X, Pan YS, Liu YC, Wang PY (2015) Protective effect of hydrogen sulfide on TNF-alpha and IFN-gamma-induced injury of intestinal epithelial barrier function in Caco-2 monolayers. Inflamm Res 64:789–797. https://doi.org/10.1007/s00011-015-0862-5 CrossRefPubMed

33.

Shen L, Black ED, Witkowski ED, Lencer WI, Guerriero V, Schneeberger EE, Turner JR (2006) Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci 119:2095–2106. https://doi.org/10.1242/jcs.02915 CrossRefPubMed

34.

Camilleri M, Madsen K, Spiller R, Van Meerveld BG, Verne GN (2012) Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 24:503–512. https://doi.org/10.1111/j.1365-2982.2012.01921.x CrossRefPubMedPubMedCentral

35.

Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD (2007) Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 56:61–72. https://doi.org/10.1136/gut.2006.094375 CrossRefPubMed

36.

Oshima T, Miwa H, Joh T (2008) Changes in the expression of claudins in active ulcerative colitis. J Gastroenterol Hepatol 23(Suppl 2):S146–S150. https://doi.org/10.1111/j.1440-1746.2008.05405.x CrossRefPubMed

37.

Furuse M, Furuse K, Sasaki H, Tsukita S (2001) Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J Cell Biol 153:263–272CrossRefPubMedPubMedCentral

38.

Amasheh M, Fromm A, Krug SM, Amasheh S, Andres S, Zeitz M, Fromm M, Schulzke JD (2010) TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling. J Cell Sci 123:4145–4155. https://doi.org/10.1242/jcs.070896 CrossRefPubMed

39.

Al-Sadi R, Guo S, Ye D, Rawat M, Ma TY (2016) TNF-alpha modulation of intestinal tight junction permeability is mediated by NIK/IKK-alpha axis activation of the canonical NF-kappaB pathway. Am J Pathol 186:1151–1165. https://doi.org/10.1016/j.ajpath.2015.12.016 CrossRefPubMedPubMedCentral

40.

Al-Sadi R, Guo S, Ye D, Ma TY (2013) TNF-alpha modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1. Am J Pathol 183:1871–1884. https://doi.org/10.1016/j.ajpath.2013.09.001 CrossRefPubMedPubMedCentral

41.

Al-Sadi RM, Ma TY (2007) IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 178:4641–4649CrossRefPubMed

42.

Suzuki T, Yoshinaga N, Tanabe S (2011) Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem 286:31263–31271. https://doi.org/10.1074/jbc.M111.238147 CrossRefPubMedPubMedCentral

43.

Ina K, Kusugami K, Yamaguchi T, Imada A, Hosokawa T, Ohsuga M, Shinoda M, Ando T, Ito K, Yokoyama Y (1997) Mucosal interleukin-8 is involved in neutrophil migration and binding to extracellular matrix in inflammatory bowel disease. Am J Gastroenterol 92:1342–1346PubMed

Title: Lignosulfonic acid attenuates NF-κB activation and intestinal epithelial barrier dysfunction induced by TNF-α/IFN-γ in Caco-2 cells
Authors: Koji Matsuhisa
Akihiro Watari
Kazuki Iwamoto
Masuo Kondoh
Kiyohito Yagi
Publication date: 01-03-2018
Publisher: Springer Singapore
Published in: Journal of Natural Medicines / Issue 2/2018
Print ISSN: 1340-3443
Electronic ISSN: 1861-0293
DOI: https://doi.org/10.1007/s11418-017-1167-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lignosulfonic acid attenuates NF-κB activation and intestinal epithelial barrier dysfunction induced by TNF-α/IFN-γ in Caco-2 cells

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Melanogenesis inhibitory activity of components from Salam leaf (Syzygium polyanthum) extract

Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis

Structure–activity relationships of flavanones, flavanone glycosides, and flavones in anti-degranulation activity in rat basophilic leukemia RBL-2H3 cells

The active glycosides from Urtica fissa rhizome decoction

Laxative effect of repeated Daiokanzoto is attributable to decrease in aquaporin-3 expression in the colon

Two new aromatic glycosides, elengiosides A and B, from the flowers of Mimusops elengi